Innovative Testing Global Cancer Diagnostics offers a proprietary blood test for early lung cancer detection targeted at high-risk populations, providing a unique product in the cancer diagnostics space that addresses a critical health need.

Market Entry Opportunity Since the Lung Cancer Test was launched in October 2014 and is priced affordably at $99, there is potential to target clinics, hospitals, and direct-to-consumer channels to expand market reach and increase sales volume.

Partnership Potential Partnering with larger biotech and healthcare companies, especially those with large sales forces such as Invitae or Guardant Health, could accelerate distribution and adoption of the test across broader markets.

Customer Engagement Despite limited employee size, engaging patient advocacy groups, healthcare providers, and insurance companies could build awareness and credibility, opening avenues for increased testing uptake.

Growth Opportunities Given the company's small revenue and early-stage position, exploring strategic investments, funding, or collaborations with established industry players could support scaling production, marketing, and sales efforts.